Drug Interactions between Reglan and sirolimus
This report displays the potential drug interactions for the following 2 drugs:
- Reglan (metoclopramide)
- sirolimus
Interactions between your drugs
metoclopramide sirolimus
Applies to: Reglan (metoclopramide) and sirolimus
MONITOR: Coadministration with gastrointestinal prokinetic agents such as cisapride, domperidone, and metoclopramide may increase the oral bioavailability of macrolide immunosuppressants. Because macrolide immunosuppressants are incompletely and variably absorbed following oral administration, increased gastrointestinal motility and gastric emptying can enhance delivery of the drugs to the small intestine where they are absorbed. In one case report, a patient with signs and symptoms of acute graft rejection in association with persistent subtherapeutic tacrolimus trough concentrations despite coadministration with ketoconazole as a pharmacokinetic booster experienced tacrolimus toxicity following the addition of metoclopramide for nausea and vomiting. Tacrolimus trough concentration exceeded 30 ng/ml, and the patient exhibited signs and symptoms suggestive of tacrolimus neuro- and nephrotoxicity. The authors theorized that the patient's persistent subtherapeutic tacrolimus levels may have been secondary to impaired gastric motility, and improvement of the condition by metoclopramide may have led to subsequent tacrolimus toxicity.
MANAGEMENT: Pharmacologic response, renal function, and macrolide immunosuppressant blood levels should be monitored more closely whenever a gastrointestinal prokinetic agent is added to or discontinue from therapy, and the immunosuppressant dosage adjusted as necessary. Patients should be advised to contact their physician if they experience potential signs and symptoms of macrolide immunosuppressant toxicity such as fever, infection, diarrhea, tremor, headache, fatigue, or lethargy.
References (3)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- (2001) "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories
- Prescott WA Jr, Callahan BL, Park JM (2004) "Tacrolimus toxicity associated with concomitant metoclopramide therapy." Pharmacotherapy, 24, p. 532-7
Drug and food interactions
metoclopramide food
Applies to: Reglan (metoclopramide)
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
sirolimus food
Applies to: sirolimus
ADJUST DOSING INTERVAL: Consumption of food can decrease the rate and extent of gastrointestinal absorption of sirolimus. Also, the consumption of grapefruit juice may result in increased sirolimus trough concentrations.
MANAGEMENT: Experts recommend that this drug be taken either at least one hour prior to eating or consistently with or without food to avoid variations in sirolimus blood levels. The manufacturer recommends against using grapefruit juice for dilution of sirolimus doses. Patients should be monitored for clinical and laboratory evidence of altered immunosuppressant effects.
References (1)
- (2001) "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.